Crispr Therapeutics AG (CRSP) stock has gained 17.83% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With CRSP Stock Today?
Crispr Therapeutics AG (CRSP) stock has risen 2.12% while the S&P 500 is unchanged 0% as of 2:25 PM on Tuesday, Dec 1. CRSP is higher by $2.69 from the previous closing price of $126.92 on volume of 1,289,654 shares. Over the past year the S&P 500 has gained 16.84% while CRSP is higher by 88.88%. CRSP lost -$3.25 per share in the over the last 12 months.
More About Crispr Therapeutics AG
CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.